Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates

Financial Performance - Rapid Micro Biosystems reported a quarterly loss of $0.26 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of$0.31 per share a year ago [1] - The company posted revenues of $7.6 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 20.70$6.15 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of$8.4 million, and for the current fiscal year, it is -$1.06 on revenues of$27 million [7] Stock Performance - Rapid Micro Biosystems shares have increased approximately 46% since the beginning of the year, outperforming the S&P 500's gain of 19.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Instruments industry, to which Rapid Micro Biosystems belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]